Gila Therapeutics, Inc.
Minneapolis, US · Founded 2014 · Delaware corporation · 3 known investors
Gila Therapeutics is a clinical-stage biotech company developing a topical lingual signaling platform that delivers micro-dose PYY dissolving on the tongue to activate brain regions regulating food intake and metabolism. Its treatments target obesity, type 2 diabetes, and associated cardiometabolic disorders.
Founders & leadership
JF
Jon FreemanExecutive
DR
Donald R. JohnsChief Medical Officer
TJ
Thomas J. VasicekNamed on SEC filing
Board
CD
Christopher de SouzaBoard director
RH
Richard HoranBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 5 of 6 rounds · 2016–2023
▶$399.6KraisedDec 2023 · 7 investors · BiotechnologyRule 506(b)
▶$399.6KraisedDec 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy BarberichDirector
- Christopher De SouzaDirector
- Praveen TyleDirector
- Jon FreemanExecutive Officer
- Thomas VasicekExecutive Officer
- Richard HoranDirector
- Scott SchorerExecutive Officer, Director
- Sangeeta KashyapExecutive Officer
- Offering amount
- $10M
- Amount sold
- $399.6K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$355.5KraisedNov 2022 · 6 investors · BiotechnologyRule 506(b)
▶$355.5KraisedNov 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SCOTT SCHORERExecutive Officer, Director
- TIMOTHY BARBERICHDirector
- CHRISTOPHER DE SOUZADirector
- JON FREEMANExecutive Officer
- RICHARD HORANDirector
- Offering amount
- $5M
- Amount sold
- $355.5K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedNov 2021 · 28 investors · BiotechnologyRule 506(b)
▶$1.3MraisedNov 2021 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard HoranDirector
- Christopher de SouzaDirector
- Scott SchorerExecutive Officer, Director
- Thomas VasicekExecutive Officer
- Jon FreemanExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$314.4KraisedMar 2019 · 3 investors · BiotechnologyRule 506(b)
▶$314.4KraisedMar 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard HoranDirector
- Thomas J. VasicekExecutive Officer, Director, Promoter
- Christopher de SouzaDirector
- Jon FreemanExecutive Officer
- Offering amount
- $2M
- Amount sold
- $314.4K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$3.3MraisedApr 2017 · 33 investors · BiotechnologyRule 506(b)
▶$3.3MraisedApr 2017 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher DeSouzaDirector
- Andres AcostaPromoter
- Richard HoranDirector
- Jon FreemanExecutive Officer
- Sergei ZolutukhinPromoter
- Thomas J. VasicekExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $3.3M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$500KofferedFeb 2017 · BiotechnologyRule 506(c)
▶$500KofferedFeb 2017 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Christopher de SouzaDirector
- Thomas J. VasicekExecutive Officer, Director, Promoter
- Andres AcostaPromoter
- Jon FreemanExecutive Officer
- Richard HoranDirector
- Sergei ZolutukhinPromoter
- Offering amount
- $500K
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAligos Therapeutics4 shared keywordsAligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
Kite Pharma4 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Galera Therapeutics4 shared keywordsGalera Therapeutics is a biotechnology company developing antibody-based and other therapeutics. This page profiles Dr. Nancy Chang, a member of the company's Board of Directors.
Companies competing with Gila Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Gila Therapeutics, Inc. do?
- Gila Therapeutics is a clinical-stage biotech company developing a topical lingual signaling platform that delivers micro-dose PYY dissolving on the tongue to activate brain regions regulating food intake and metabolism. Its treatments target obesity, type 2 diabetes, and associated cardiometabolic disorders.
- Who are Gila Therapeutics, Inc.'s investors?
- Gila Therapeutics, Inc.'s investors include Broadview Ventures, iSelect Fund, Elephant Partners.
- How much funding has Gila Therapeutics, Inc. raised?
- Gila Therapeutics, Inc. has disclosed $5.7M raised across 5 of its 6 known rounds.
- Where is Gila Therapeutics, Inc. headquartered?
- Gila Therapeutics, Inc. is headquartered in Minneapolis, US.